Washington, May 24 (IANS) The US Trade Representative (USTR) has kicked off a process to collect public comments on cases of the suppression of pharmaceutical product prices below market value in foreign countries, as it seeks to stop what it calls “freeloading” on US-financed medical research.
The USTR’s efforts to collect comments by June 27 came after President Donald Trump signed an executive order earlier this month to lower the cost of prescription drugs for American citizens to match prices paid in other countries, reports Yonhap news agency.
The move spawned concerns that South Korean pharmaceutical firms could come under U.S. scrutiny, given that the USTR has taken issue with the Asian country’s pricing policies for pharmaceuticals.
“USTR invites comments from interested parties regarding any act, policy, or practice that may be unreasonable or discriminatory or that may impair United States national security and that has the effect of forcing American patients to pay for a disproportionate amount of global pharmaceutical research and development,” it said on a public docket.
In an annual report on foreign trade barriers released in March, the USTR pointed out the U.S. pharmaceutical and medical device industries’ concerns over what they describe as a lack of transparency in Korea’s pricing and reimbursement policies and a lack of substantive opportunities for stakeholder input into proposed policy changes.
Meanwhile, US President Donald Trump has threatened to roll out 25 per cent tariffs by the end of next month on smartphones made by Apple, Samsung Electronics Co. and other companies if they are not manufactured in the United States. Trump issued the threat hours after he warned in a social media post that if iPhones are not made in the U.S., a “tariff of at least 25 percent must be paid by Apple to the U.S.”
Trump reiterated that companies manufacturing their product in the US would not face tariffs.
–IANS
na/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
